2-chloro-3-(trifluoromethyl)benzenesulfonyl chloride | 1214346-10-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-chloro-3-(trifluoromethyl)benzenesulfonyl chloride
• 英文别名: 2-Chloro-3-(trifluoromethyl)benzene-1-sulfonyl chloride
• CAS: 1214346-10-7
• 化学式: C₇H₃Cl₂F₃O₂S
• 分子量: 279.067
• InChiKey: QHZPYQQXLBLSLZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  42.5
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  1-bromo-2-chloro-3-(trifluoromethyl)benzene 在 异丙基氯化镁 、 1,4-diazabicyclo[2.2.2]octane-triethylenediamine-bis(sulfur dioxide) 、 N-氯代丁二酰亚胺 作用下， 以 四氢呋喃 为溶剂， 反应 4.0h， 生成 2-chloro-3-(trifluoromethyl)benzenesulfonyl chloride
  参考文献：
  名称：

  [EN] ARYLSULFONAMIDE DERIVATIVES AS MGLUR4 NEGATIVE ALLOSTERIC MODULATORS
  [FR] DÉRIVÉS D'ARYLSULFONAMIDE EN TANT QUE MODULATEURS ALLOSTÉRIQUES NÉGATIFS DE MGLUR4

  摘要：

  本发明提供了具有一般式（I）的新芳基磺酰胺化合物，其中L、R1、R2、R3和R4如本文所述，包括这些化合物的组合物，制造这些化合物的方法以及将这些化合物用作mGLUR4负变构调节剂的方法。

  公开号：

  WO2021028512A1

文献信息

• Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases
  申请人：Bora Martin Keenan

  公开号：US20050004167A1

  公开（公告）日：2005-01-06

  The invention relates to BCAT inhibitor compounds of formula (I) and use thereof for treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the overstimulation of the excitatory amino acids, treating anxiety, psychosis, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine headache, chronic pain, neuropathic pain, Parkinson's disease, diabetic retinopathy, glaucoma, CMV retinitis, urinary incontinence, opioid tolerance or withdrawal, and inducing anesthesia, as well as for enhancing cognition.

  本发明涉及公式（I）的BCAT抑制剂化合物及其用于治疗或预防与中风、缺血、中枢神经系统创伤、低血糖和手术相关的神经元丢失，以及治疗神经退行性疾病，包括阿尔茨海默病、肌萎缩性侧索硬化症、亨廷顿病和唐氏综合症，治疗或预防兴奋性氨基酸过度刺激的不良后果，治疗焦虑、精神病、惊厥、氨基糖苷类抗生素引起的听力损失、偏头痛、慢性疼痛、神经病性疼痛、帕金森病、糖尿病视网膜病变、青光眼、巨细胞病毒性视网膜炎、尿失禁、阿片类耐受或戒断，以及诱导麻醉和增强认知功能。
• BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES
  申请人：Warner-Lambert Company LLC

  公开号：EP1320523A2

  公开（公告）日：2003-06-25
• ARYLSULFONAMIDE DERIVATIVES AS MGLUR4 NEGATIVE ALLOSTERIC MODULATORS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP4013495A1

  公开（公告）日：2022-06-22
• ARYLSULFONAMIDE DERIVATIVES
  申请人：Hoffmann-La Roche Inc.

  公开号：US20220169599A1

  公开（公告）日：2022-06-02

  The present invention provides new arylsulfonamide compounds having the general formula (I) wherein L, R 1 , R 2 , R 3 and R 4 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
• [EN] BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES<br/>[FR] INHIBITEURS D'AMINOTRANSFERASE DEPENDANT D'AMINOACIDES A CHAINE RAMIFIEE, ET LEUR UTILISATION DANS LE TRAITEMENT DE MALADIES NEURODEGENERATIVES
  申请人：WARNER LAMBERT CO

  公开号：WO2002024672A2

  公开（公告）日：2002-03-28

  The invention relates to BCAT inhibitor compounds of formula (I) and use thereof for treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the overstimulation of the excitatory amino acids, treating anxiety, psychosis, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine headache, chronic pain, neuropathic pain, Parkinson's disease, diabetic retinopathy, glaucoma, CMV retinitis, urinary incontinence, opioid tolerance or withdrawal, and inducing anesthesia, as well as for enhancing cognition.